Strengthening Innovation: China’s New Era of Drug Regulatory Data Protection

On May 15, 2026, China officially launched its comprehensive Drug Regulatory Data Protection (RDP) regime, introduced by the National Medical Products Administration (NMPA) under the Measures for the Implementation of Drug Regulatory Data Protection. This new framework signifies a pivotal transformation in China's pharmaceutical landscape, aimed at fostering innovation, addressing public medication needs, and aligning with international standards.

The Three-Tiered Protection System

The new measures establish a structured protection system consisting of three distinct periods—6, 4, and 3 years—tailored to the category of the drug. This approach ensures that subsequent applicants cannot utilize the original developer's data without consent during these specified periods.

As detailed in the Appendix Tables of the Measures for the Implementation of Drug Regulatory Data Protection, the protection tiers are defined as follows:

• Innovative Drugs: Both domestically developed and foreign-origin innovative drugs (Class 1) are granted 6 years of protection from their first domestic marketing approval date.
• Modified New Drugs: These products typically receive 4 years of protection. However, if the modified drug introduces a globally new indication that is not yet approved in China, a 6-year protection period applies.
• First Generics/Biosimilars: The first approved generic or biosimilar product referencing an overseas-approved originator drug that is not yet approved domestically is afforded 3 years of protection.
• New Indications: New indications for originator drugs approved overseas but not in China can receive 6 years of protection if the indication is globally new or 4 years for any subsequent additions.

Scope and Definition of Protected Data

The data protection applies to independently obtained and undisclosed test data submitted during the registration process. The NMPA clarifies that "undisclosed" signifies that the complete dataset remains confidential, even if brief summaries or clinical trial results are publicly available.

For innovative drugs, protection encompasses the entire marketing authorization dossier that demonstrates safety, efficacy, and quality control. In the case of modified drugs, protection is restricted to the new clinical trial data that shows a significant clinical advantage over existing treatments. Importantly, data related to bioavailability, bioequivalence, and vaccine immunogenicity are explicitly excluded from this protection.

Implementation and Enforcement Mechanism

Under this new regulatory framework, the NMPA will not approve any marketing application that relies on protected data without the holder's consent during the exclusivity period. However, this system does not confer a total market monopoly; other applicants who independently acquire their own data through trials may still obtain marketing approval, though they will not receive an additional data protection period.

Applicants must submit their RDP request concurrently with their drug registration application. For drugs already approved or under review between May 15, 2020, and May 14, 2026, a retroactive application window has been established, requiring filings by June 5, 2026.

Strategic Implications: The "Dual-Moat" Strategy

This regime introduces a "dual-moat" strategy for pharmaceutical companies, enabling them to layer administrative data exclusivity atop existing patent protections. This approach is crucial for drugs approaching a "patent cliff." For example, even after patent expiration, originators can maintain market exclusivity if their clinical trial data remains protected.

For generic manufacturers, these new rules complicate market entry, as they must now wait for both patent and data protection periods to lapse unless they are willing to fund and conduct their independent clinical trials.